IVPost
Dual-Hormone, Artificial Pancreas with Insulin and Pramlintide Significantly Improves Glucose Levels, Compared to Insulin-Only Artificial Pancreas
- Details
- Written by Michelle Kirkwood
- Category: Latest News
Orlando, Florida - A dual-hormone, artificial pancreas delivering rapid insulin and the drug pramlintide improved glucose control and reduced glucose variability in adults with type 1 diabetes (T1D) compared to an insulin-only, first-generation artificial pancreas, according to the study, “Insulin-plus-Pramlintide Artificial Pancreas in Type 1 Diabetes—Randomized Controlled Trial,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center Convention Center.
Identifying and Reducing Gender Gaps in Diabetes—Care, Research and the Health Care Profession
- Details
- Written by Michelle Kirkwood
- Category: Medical News
Orlando, Florida - Gender disparities exist in clinical practice and academic medicine when it comes to career opportunities and treatment. According to a November 2017 report from the U.S. Bureau of Labor Statistics (BLS), nearly 47 percent of the U.S. workforce are women. In 2011, the BLS also reported that only 34 percent of physicians and surgeons were women.
Stakeholder Nominations Open to Help Guide Research Grant Process
- Details
- Written by IVPost
- Category: Health News
The American Cancer Society is seeking individuals with a strong personal interest in cancer to participate in its research and training grants peer review process. “Stakeholders” have been an important part of the Society’s grant review process since 1999. They provide a unique perspective from the cancer experience to help ensure sound research funding decisions.
Next-generation ALS drug silences inherited form of the disease in animal models
- Details
- Written by Christopher G. Thomas
- Category: Health News
Washington, DC - NIH-funded researchers delayed signs of amyotrophic lateral sclerosis (ALS) in rodents by injecting them with a second-generation drug designed to silence the gene, superoxide dismutase 1 (SOD1). The results, published in the Journal of Clinical Investigation, suggest the newer version of the drug may be effective at treating an inherited form of the disease caused by mutations in SOD1. Currently, the drug is being tested in an ALS clinical trial (NCT02623699).
NIH renews NeuroNEXT for neurological clinical research
- Details
- Written by Barbara McMakin
- Category: Latest News
Washington, DC - The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, a research program that helps streamline Phase II clinical trials for brain disorders, has been renewed for five more years, with several new centers joining the program. NeuroNEXT is supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
NIH expands program that conducts large-scale clinical trials in real-world settings
- Details
- Written by IVPost
- Category: Health News
Washington, DC - The National Institutes of Health’s Health Care Systems (HCS) Research Collaboratory, which involves health care systems in conducting large-scale clinical studies, has announced five new research awards — totaling $4.15 million for a one-year planning phase, with an estimated $30.85 million expected for four subsequent years of study implementation. The HCS Research Collaboratory was developed by the NIH Common Fund in 2012 and is administered by the National Center for Complementary and Integrative Health (NCCIH) and the National Institute on Aging (NIA).
Page 3 of 50